Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards

25-Nov-2009 - Amgen was honored with two 2009 Scrip Awards, winning for Best Overall Pipeline and for Best New Drug for Nplate® (romiplostim), at a ceremony in London. The Best Overall Pipeline award was presented to Amgen by Scrip in recognition of the size, quality, novelty and market potential of the ...

Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity

02-Nov-2009 - Amylin Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited announced that they have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related ...

Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon

26-Oct-2009 - Potentia Pharmaceuticals announced that it has entered into licensing and purchase option agreements with Alcon Research, Ltd., a wholly-owned subsidiary of Alcon, Inc.. The agreements provide Alcon with a license to develop Potentia's leading drug candidate, POT-4, for the treatment of AMD. The ...

Abbott to Acquire Solvay Pharmaceuticals Business

Diversifies Abbott's pharmaceutical products, expanding international growth platform

01-Oct-2009 - Abbott announced a definitive agreement with the Solvay Group for Abbott to acquire Solvay's pharmaceuticals business for EUR 4.5 billion(US$6.6 billion) in cash, providing Abbott with a large and complementary portfolio of pharmaceutical products and a significant presence in key global emerging ...

Raptor Pharmaceuticals and TorreyPines Therapeutics Receive Stockholder Approvals to Merge

Merger to Create NASDAQ-Listed Biopharmaceutical Company named Raptor Pharmaceutical Corp.

01-Oct-2009 - Raptor Pharmaceuticals Corp. announced that its stockholders approved the proposals to complete the proposed merger with TorreyPines Therapeutics, Inc. at its annual meeting of stockholders. Concurrently, at the annual meeting of its stockholders, TorreyPines stockholders approved all of the ...

Abbott to Acquire Visiogen, Expanding Vision Care Portfolio

07-Sep-2009 - Abbott announced a definitive agreement to acquire Visiogen, Inc. for $400 million in cash, providing the company with a next-generation accommodating intraocular lens (IOL) technology to address presbyopia for cataract patients. Visiogen, a privately held company based in Irvine, Calif., with ...

Bayer Acquires Two Prescription Dermatology Product Lines from SkinMedica in the U.S.

07-Sep-2009 - Intendis GmbH, which is part of Bayer HealthCare, announced that it has signed an agreement to acquire two prescription dermatology product lines from SkinMedica, Inc. Both Desonate® and NeoBenz® Micro are currently marketed in the U.S. by SkinMedica, Inc. Under the transaction, which is still ...

Syngenta to Acquire Monsanto's Global Sunflower Assets

11-Aug-2009 - Monsanto Company announced that it has entered into an agreement to sell its global sunflower assets to Syngenta. Under the terms of the agreement, Syngenta will purchase assets and assume liabilities of Monsanto associated with its global hybrid sunflower seed business for $160 million. The ...

Agilent Technologies to Acquire Varian, Inc. for $1.5 Billion

03-Aug-2009 - Agilent Technologies Inc. and Varian, Inc. announced that they have signed a definitive agreement for the acquisition by Agilent of Varian. Agilent will pay $52 cash per share of common stock for Varian in a transaction that represents a premium of approximately 35% to Varian’s closing price on ...

Gilead Sciences Announces Agreement With Tibotec Pharmaceuticals

20-Jul-2009 - Gilead Sciences, Inc. announced that it has entered into a license and collaboration agreement with Tibotec Pharmaceuticals for the development and commercialization of a new once-daily fixed-dose antiretroviral regimen containing Gilead’s Truvada® (emtricitabine and tenofovir disoproxil ...